Safety profile of recombinant factor VIIa
- 1 January 2004
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 41, 101-108
- https://doi.org/10.1053/j.seminhematol.2003.11.019
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Preliminary Experience with the Use of Recombinant Factor VIIa to Treat Coagulation Disturbances in Pediatric PatientsSouthern Medical Journal, 2003
- The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasisDisease-a-Month, 2003
- Treatment of Severe Pulmonary Hemorrhage With Activated Recombinant Factor VII (rFVIIa) in Very Low Birth Weight InfantsJournal of Perinatology, 2002
- Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIaBone Marrow Transplantation, 2002
- Successful Use of Recombinant Activated Factor VII for Trauma-Associated Hemorrhage in a Patient without Preexisting CoagulopathyPublished by Wolters Kluwer Health ,2002
- Active site-inhibited seven: Mechanism of action including signal transductionSeminars in Hematology, 2001
- Off-label use of recombinant factor VIIa in patients following bone marrow transplantationBone Marrow Transplantation, 2001
- Early treatment with recombinant factor VIIa results in greater efficacy with less productEuropean Journal of Haematology, 1998
- Approaches towards successful home treatment in patients with inhibitorsEuropean Journal of Haematology, 1998
- Plasma levels of activated FVII in various diseasesBlood Coagulation & Fibrinolysis, 1996